374 related articles for article (PubMed ID: 33569305)
1. Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
Pavan A; Bragadin AB; Calvetti L; Ferro A; Zulato E; Attili I; Nardo G; Dal Maso A; Frega S; Menin AG; Fassan M; Calabrese F; Pasello G; Guarneri V; Aprile G; Conte P; Rosell R; Indraccolo S; Bonanno L
Transl Lung Cancer Res; 2021 Jan; 10(1):202-220. PubMed ID: 33569305
[TBL] [Abstract][Full Text] [Related]
2. Impact of
Bange E; Marmarelis ME; Hwang WT; Yang YX; Thompson JC; Rosenbaum J; Bauml JM; Ciunci C; Alley EW; Cohen RB; Langer CJ; Carpenter E; Aggarwal C
JCO Precis Oncol; 2019; 3():. PubMed ID: 31428721
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes and immune phenotypes associated with
Malhotra J; Ryan B; Patel M; Chan N; Guo Y; Aisner J; Jabbour SK; Pine S
J Thorac Dis; 2022 Jun; 14(6):1772-1783. PubMed ID: 35813711
[TBL] [Abstract][Full Text] [Related]
5. Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.
Olsen A; Lebedeva A; Nosova P; Nikulin V; Sharova M; Ignatova E; Mileyko V; Ivanov M
Tumori; 2024 Apr; 110(2):146-152. PubMed ID: 37817679
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
7. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
8. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
9. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico A; De Giglio A; Parisi C; Gelsomino F
Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
[TBL] [Abstract][Full Text] [Related]
10. STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications.
Krishnamurthy N; Goodman AM; Barkauskas DA; Kurzrock R
Eur J Cancer; 2021 May; 148():215-229. PubMed ID: 33744718
[TBL] [Abstract][Full Text] [Related]
11. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.
Torralvo J; Friedlaender A; Achard V; Addeo A
Cancer Genomics Proteomics; 2019; 16(6):577-582. PubMed ID: 31659111
[TBL] [Abstract][Full Text] [Related]
12. A Critical Review of the Prognostic and Predictive Implications of
Manolakos P; Ward LD
J Pers Med; 2023 Jun; 13(6):. PubMed ID: 37373999
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China.
Li Q; Zhou Q; Zhao S; Wu P; Shi P; Zeng J; Xiong X; Chen H; Kittaneh M; Bravaccini S; Zanoni M; Zhou C; Zhang J
Transl Lung Cancer Res; 2022 Oct; 11(10):2136-2147. PubMed ID: 36386464
[TBL] [Abstract][Full Text] [Related]
14. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
15. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract][Full Text] [Related]
16. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
17. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
[TBL] [Abstract][Full Text] [Related]
18. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
[No Abstract] [Full Text] [Related]
19. Primary Resistance to Immune Checkpoint Blockade in an
Kwack WG; Shin SY; Lee SH
Onco Targets Ther; 2020; 13():8901-8905. PubMed ID: 32982282
[TBL] [Abstract][Full Text] [Related]
20. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]